The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia

Participants diagnosed with AGA will be randomized into one of the two treatment arms
outlined below, and will take the assigned treatment for a total duration of 12 months.
Medications will be dispensed by a nurse who is blinded to the participants within each
treatment group. Global photograph assessment and participant questionnaires at 0, 4, 8 and
12 months will be the primary means to determine improvement in hair loss.

Compare the following interventions in treating postmenopausal female AGA:

A) Combination 5% Minoxidil and 200mg Spironolactone (Combination Group) B) 5mg Finasteride
with placebo topical preparation (Single Group)

Inclusion Criteria:

- female

- postmenopausal (>60 years old or with total hysterectomy)

- diagnosed with androgenetic alopecia

- no chemical processing or changes in hair products throughout the study

Exclusion Criteria:

- men

- premenopausal women (<60 or without hysterectomy)

- participants allergic to any of the study medications (minoxidil, finasteride,
spironolactone)

- participants with other co-existing forms of alopecia (traction, alopecia areata, or
scarring alopecias)

- participants with obstructive uropathy or advanced liver disease

- prior hair loss treatment within the last 6 months

- hair loss from the chemotherapy or other medication-induced alopecia

- Hair loss for greater than 5 years, as medical therapy is unlikely to have much
effect at restoring hair follicles inactive for that long of a period.